NSUBUGA GERALD
ID: UNCST-2021-R011633
|
Feasibility and Acceptability Using Umbilical Cord Blood for Cancer Treatment through Stem Cell Transplantation: A Multi-Center Study Involving Pregnant Mothers, Health Workers, and Cancer Patients in Collaboration with the Uganda Blood Transfusion Service
REFNo: HS6131ES
General Objective
To assess the feasibility and acceptability of collecting and using umbilical cord blood for stem cell transplantation in cancer patients based on the perceptions and readiness of pregnant mothers, health professionals, and cancer patients in selected public health facilities in Uganda.
Specific Objectives
1. To determine the level of awareness and knowledge about umbilical cord blood stem cell transplantation among pregnant mothers, health professionals, and cancer patients.
2. To assess the willingness of pregnant mothers to donate umbilical cord blood for therapeutic use.
3. To evaluate the preparedness of health professionals to support UCB collection, processing, and utilization.
|
Kampala,
Wakiso,
|
Uganda |
2026-06-05 15:35:56 |
2029-06-05 |
385 |
The study population will comprise diverse groups of individuals relevant to the establishment of an umbilical cord blood bank for allogeneic stem cell transplantation at Uganda Blood Transfusion Service (UBTS).
Expectant Mothers:
Pregnant women aged 18 to 45 years attending antenatal clinics at selected hospitals will form the primary group. This age range represents women of reproductive age with the potential to donate umbilical cord blood. Expectant mothers from different tribes and ethnic backgrounds across Uganda will be included to ensure diversity and representativeness.
Healthcare Providers:
Participants will include medical doctors, nurses, midwives, and laboratory personnel involved in maternal and child health, blood banking, and oncology services. Their insights will be critical in understanding technical and operational needs. Both male and female providers will be included, with no age restrictions, focusing on those actively working in relevant departments.
UBTS Staff and Policymakers:
Staff from UBTS, including management and technical personnel, as well as policymakers from the Ministry of Health, will participate to provide perspectives on regulatory, logistical, and financial requirements.
Community Representatives:
Community leaders and opinion leaders from various regions and ethnic groups will also be engaged to capture cultural attitudes and perceptions about umbilical cord blood donation. |
Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Namulema Edith
ID:
|
Exploring the feasibility and safety of using the ‘LeVe Neonatal CPAP System’ to assist neonates with signs of respiratory distress at Mengo Hospital
REFNo: HS7747ES
1) Feasibility Objective - To determine the proportion of neonates in whom the LeVe CPAP device can be successfully initiated and maintained for the entire study duration.
2) Safety Objective - To determine the incidence of CPAP-related adverse events occurring within the first 7 days of CPAP therapy.
3) Respiratory Effectiveness Objective - To assess the early respiratory response to CPAP within 2 hours of initiation and for the entire study duration using SpO₂, FiO₂ measures and the Silverman-Andersen respiratory distress score.
4) Prematurity-Related Outcome Objective - To determine the incidence of survival to discharge, bronchopulmonary dysplasia, and retinopathy of prematurity.
5) To explore healthcare workers' perceptions and experiences regarding CPAP training adequacy, their confidence in using neonatal CPAP, and their views on how CPAP implementation influences neonatal respiratory outcomes within their clinical setting
|
Kampala, Mengo
|
Uganda |
2026-05-28 16:35:26 |
2029-05-28 |
40 |
Neonates Age: 0–28 days of life.
|
University of Leeds |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Henry Mugerwa
ID: UNCST-2019-R000420
|
A Phase I/II clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ITU512 in healthy participants and patients with
sickle cell disease
REFNo: HS6925ES
1.To assess the safety and tolerability
of ITU512 in healthy participants
2.To assess the safety and tolerability
of ITU512 in participants with SCD
3.To assess the effect of ITU512 on
fetal hemoglobin expression
|
Wakiso, Sabagabo
|
Uganda |
2026-05-22 16:52:18 |
2029-05-22 |
89 |
children, adults, mela and female |
Norvatis |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Elizabeth Kaudha
ID: UNCST-2025-R017151
|
A Phase 3b, open-label, multicenter, continued access study for participants transitioning from ViiV Healthcare-sponsored or ViiV Healthcare collaborative parent studies for HIV treatment.
REFNo: HS7588ES
The main objective of the study is to provide continued access to study interventions for participants who were enrolled and treated in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies and who continue to experience clinical benefit, and to describe the continued use and safety of the study intervention.
The specific objectives of this study are, Reasons for discontinuation of study intervention Incidence and outcome of serious adverse events (SAEs) Incidence and outcome of adverse events of special interest (AESIs)
|
Kampala, Mulago II Parish
Wakiso, Lubowa Parish
Kampala, Kansanga parish
|
Uganda |
2026-05-15 18:55:49 |
2029-05-15 |
130 |
Participants eligible for this study are individuals with HIV-1 who received the study intervention and completed the protocol-defined treatment period in ViiV Healthcare-sponsored or ViiV Healthcare-collaborative parent studies, and who, at the time of transition to this continued access study, experience clinical benefit as determined by the Investigator of Record from the parent study intervention |
ViiV Healthcare UK Limited, 79 New Oxford Street, London, WC1A 1DG, United Kingdom |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Crispus Natwijuka
ID: UNCST-2024-R016280
|
TESTING NRIMS VERSION 2
REFNo: SIR662ES
testing testing testing
|
|
Uganda |
2026-05-06 10:30:12 |
2029-05-06 |
|
|
|
Engineering and Technology |
Clinical Trial |
Non-degree Award |
|
Francis Ssali
ID: UNCST-2021-R012134
|
A5424
Menopausal Hormone Therapy for Women Living with HIV (HoT)
REFNo: HS7391ES
1.2 Primary Objective
1.2.1 Determine the effects of HT on VMS in WLWH in the late menopausal transition or early postmenopause.
1.3 Secondary Objectives
1.3.1 Evaluate the safety and tolerability of HT as compared to placebo.
1.3.2 Determine the effect of HT on neurocognition.
1.3.3 Determine the effect of HT on mood.
1.3.4 Determine the effect of HT on sleep.
1.3.5 Determine the effect of HT on quality of life.
1.3.6 Determine the effect of HT on sexual function.
1.3.7 Determine the effect of HT on weight, waist circumference, and waist-to-hip ratio.
1.4 Exploratory Objectives
1.4.1 Determine the effect of HT on markers of bone turnover.
1.4.2 Determine the effect of HT on markers of cardiometabolic health.
1.4.3 Determine the effect of HT on systemic markers of inflammation and immune activation.
1.4.4 Determine the effect of HT on HIV reservoir size, clonality, and activity.
1.4.5 Determine the effect of HT on measures of physical function.
1.4.6 Determine the effect of HT on the rectal and vaginal microbiome.
1.4.7 Explore the effect of HT on all primary and secondary outcomes by antiretroviral regimen.
1.4.8 Explore exposure-response relationships between estradiol pharmacokinetics (PK) and study outcomes in those treated with estradiol.
1.4.9 Evaluate acceptability and feasibility of ambulatory monitors for VMS and sleep on a subset of participants.
1.4.10 Explore agreement between subjective VMS frequency with objective VMS frequency in a subset of participants.
|
Kampala, Seguku
|
Uganda |
2026-04-24 13:20:15 |
2029-04-24 |
96 |
40-60 YEARS OLD WOMEN LIVING WITH HIV/AIDS.
ENGLISH AND LUGANDA UNDERSTANDING PARTICIPANTS |
National Institute of Allergy and Infectious Diseases |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Yudaya Nakyeyune
ID: UNCST-2026-R024597
|
Using Play in Culturally Responsive Ways to Enhance Children’s Numeracy Skills Achievement in Refugee-Hosting ECD Centers in Kampala
REFNo: SS5116ES
1. To analyze children's voices of learning through play in refugee hosting ECD centers in Kampala.
2. To identify the challenges teachers encounter when using play in the teaching of numeracy in refugee hosting ECD centers in Kampala
3 To establish the impact of engagement in Continuing Professional Development (CPD) on teachers' knowledge regarding the use of play-based methods in culturally responsive ways in refugee hosting ECD centers in Kampala
4. To assess the impact of engagement in culturally responsive learning through play activities on children's numeracy achievement in refugee hosting ECD venters in Kampala
|
Kampala, Makerere
|
Uganda |
2026-04-20 16:47:28 |
2029-04-20 |
264 |
The study sample will consist of eight centers, 24 teachers (three per center), and 480 children (60 per center; 240 children in each arm). Within each center, three P1–P3 classes, each with approximately 20 children, participate. Randomization will be stratified based on center characteristics, specifically the proportion of refugee children (high or low), and will be conducted using computer-generated random numbers. |
Self Sponsored |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Fred Kigozi
ID: UNCST-2025-R021423
|
Postprandial effect of isocaloric challenge meals enriched with indigenous fruits and vegetables on glucose metabolism in individuals with type 2 diabetes in Wakiso District, Uganda.
REFNo: HS7347ES
General Objective
To evaluate the postprandial effect of isocaloric challenge meals enriched with indigenous fruits and vegetables on glucose metabolism among people living with type 2 diabetes in Wakiso district, Uganda.
Specific Objectives
1.To assess the acute postprandial effects of isocaloric challenge meals enriched with indigenous fruits and vegetables on incremental area under the curve (iAUC) blood glucose levels.
2.To assess the acute postprandial effects of isocaloric challenge meals enriched with indigenous fruits and vegetables on iAUC blood triglyceride levels.
|
Wakiso, Kitende
|
Uganda |
2026-04-20 10:47:24 |
2029-04-20 |
8 |
People living with type 2 diabetes aged 30-60 years |
1 |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
William Worodria Ofuti
ID: UNCST-2022-R010915
|
Program for Rifampicin-Resistant Disease with Stratified Medicine for TB” (PRISM-TB)
REFNo: HS7398ES
To identify, among participants with fluoroquinolone-susceptible multidrug-resistant/rifampicin-resistant tuberculosis (FQ-S MDR/RR-TB), the preferred BPaLM strategy of 13 or 17 weeks for participants stratified to receive shorter treatment and 17 or 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, and to evaluate whether this BPaLM strategy has noninferior efficacy to the control strategy at Week 73.
1. To evaluate whether a BPaLM strategy of 17 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
2. To evaluate whether a BPaLM strategy of 17 weeks for all participants has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
3. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 24 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
4. To evaluate whether a BPaLM strategy of 13 weeks for participants stratified to receive shorter treatment and 17 weeks for participants stratified to receive longer treatment, as defined by a prespecified stratification algorithm, has superior DOOR probability to the control strategy combining efficacy at the end of follow-up (a minimum of 28 weeks post-randomization) and safety at 28 weeks post-randomization.
5. To compare the proportion of participants who experience grade 3 or higher adverse events by Week 28 in the preferred BPaLM strategy to the control strategy.
6. To compare the proportion of participants who experience adverse events of special interest by Week 28 in the preferred BPaLM strategy to the control strategy.
7. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive shorter treatment.
8. To compare the proportion of participants who experience a TB-related unfavorable outcome at Week 73 on the preferred BPaLM strategy with the control strategy, among participants stratified to receive longer treatment.
9. To evaluate the pharmacokinetics of all drugs in the BPaLM regimen with an additional focus on bedaquiline elimination (Stages 1 and 2).
10. To determine the dose-response and exposure-response relationships between study drug estimated PK parameters with efficacy and toxicity (Stages 1 and 2).
11. To evaluate the feasibility and acceptability of treatment stratification in the context of treatment for MDR/RR-TB from the participant and the health system perspective (Stages 1 and 2).
|
Kampala,
|
Uganda |
2026-04-10 18:15:27 |
2029-04-10 |
60 |
All |
SMART TB |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Richard Idro
ID: UNCST-2021-R013599
|
Dihydroartemisinin-piperaquine for the post-discharge management of children with severe acute malnutrition in Malawi and Uganda; A multicentre, parallel-group, two-arm, randomised, double-blind superiority trial [Short Title: Post-discharge Malaria Chemoprevention - SAM (PDMC-SAM)]
REFNo: HS7291ES
To determine if 4 months of PDMC with dihydroartemisinin piperaquine (DP) compared to placebo is superior in reducing hospital readmissions and death by 6 months in children aged <5 years admitted with ‘SAM’ who are clinically stable and ready to be discharged to OTC.,
|
Jinja, Nalufenya
|
Uganda |
2026-04-10 18:06:21 |
2029-04-10 |
Overall 560, about 300 in Uganda |
Children, aged <5 years, with severe acute malnutrition [defined as weight-for-height <-3 SD-score or mid-upper circumference <115 mm, or symmetrical pitting oedema], discharged through/attending Outpatient Therapeutic care (OTC) clinics. |
Training and Research Unit of Excellence, Blantyre, Malawi |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Waiswa Peter
ID: UNCST-2020-R014921
|
An effectiveness-implementation trial of a peer mentorship intervention to help women navigate barriers to contraceptive use in rural Uganda
REFNo: HS7355ES
Main objective
: Our main aim is to increase women’s ability to overcome barriers to contraceptive use and to support adoption of self-injectable contraception. After promising findings in our pilot study, we propose to build on our strong, ongoing partnership between Makerere University in Uganda and the University of California, San Francisco to test “I-CAN” intervention on a larger scale.
Objectives
1. To test the effectiveness of a peer mentorship intervention on contraceptive use and contraceptive self-injection (Aim 1).
2. To examine the process of implementing I-CAN intervention; the ICAN’s reach to mentees, differential effectiveness, adoption and maintenance by mentors, implementation fidelity and innovations, and contextual factors (Aim 2)
3. To examine the cost-effectiveness of the peer mentorship intervention versus standard of care (counselling by health facility or community health workers) in supporting contraceptive use and contraceptive self-injection (Aim 3).
|
Iganga, Yet to be selectedYet to be selecetd
Kole, Yet to be selecetd
|
Uganda |
2026-04-02 12:45:33 |
2029-04-02 |
The trial is powered for all outcomes. 26 villages per arm (52 total clusters) with a cluster size of 30 households (total N=1,560 households at each timepoint) will allow us ≥80% power (alpha=0.05) to detect the following effect sizes among women ages 18-49 between arms at 24- months: |
The primary study population will include women ages 18-49 years form Iganga and Kole districts; Basoga nd langi tribes |
National Institutes for Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Victoria Ndyanabangi
ID: UNCST-2021-R012645
|
IMPAACT 2024- Protocol Titled: Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Study ID #38747,IND #171439
REFNo: HS6638ES
To determine weight-band dosing of a once-daily, 28-day regimen of isoniazid (INH) and rifapentine (RPT) (1HP) for the prevention of tuberculosis (TB) in children living with and without HIV.
Primary Objectives
Cohort 1 and Cohort 2
To determine the weight-band dosing of RPT taken as part of the 1HP regimen by evaluating:
⎯ PK RPT exposures among children with and without HIV
⎯ Safety and tolerability of the 1HP regimen among children with HIV while receiving twice-daily
DTG and children without HIV through 28 days of dosing
Cohort 2
• To evaluate the effect of RPT taken as part of the 1HP regimen on the PK of DTG
Secondary Objectives
Cohort 1 and Cohort 2
To evaluate the effect of covariates including age, weight, sex, ethnicity, nutritional status, and HIV-1 status on the PK of RPT taken as part of the 1HP regimen
• To evaluate the safety of the 1HP regimen through 24 weeks of follow-up
• To evaluate the palatability and acceptability of the 1HP regimen
• To evaluate adherence to the 1HP regimen
Cohort 2
• To evaluate the safety and tolerability of twice-daily DTG through 42 days among children with HIV who are receiving 1HP
• To evaluate virologic control (less than 200 copies/mL) at Day 42 among children taking a DTG-Based ARV treatment regimen co-administered with 1HP
|
Kampala, All Parishes
|
Uganda |
2026-03-30 12:54:54 |
2029-03-30 |
48 |
Children living without HIV (Cohort 1) and children living with HIV (Cohort 2) at risk of TB disease who are less than 13 years of age. Children in Cohort 2 will receive an antiretroviral (ARV) treatment regimen containing dolutegravir (DTG). |
National Institute of Allergy and Infectious Diseases Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institute of Mental Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Monicah Agaba
ID: UNCST-2024-R004221
|
The effect of a peer modelled complex behavioural change intervention on the cardio-metabolic health of women in Mbarara City, Uganda
REFNo: HS7211ES
1. To assess the effect of the a complex behavioural change intervention on the central adiposity of the WRA.,To evaluate the overall effectiveness of a peer modelled complex behavioural change intervention on the cardio-metabolic health of women through a cluster randomised control trial.,
|
Mbarara, Kakoba
|
Uganda |
2026-03-25 10:44:24 |
2029-03-25 |
157 |
18 to 49 years
Women of reproductive age
All tribes
Residents of Kakoba Ward within Mbarara City |
Katholieke Universiteit Leuven |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Abdul Malik Muwanga
ID: UNCST-2026-R024094
|
Developing Leadership Skills of ECCE Center Management Committees in Palorinya Refugee Hosting ECCE centers - Obongi District
REFNo: SS5010ES
1 Identify gaps in the leadership skills of CMCs in refugee hosting ECCEcenters in Palorinya refugee settlement.
2 Develop a training program to strengtheb the leadership skills of CMCs in enhancing children’s learning outcomes in Palorinya refugee settlement.
3 Implement a training program to develop the leadership skills of CMCs to improve children’s learning outcomes in refugee-hosting ECCE centers in Palorinya.
4 Evaluate the effectiveness of a training program in developing the leadership skills of ECCECenter Management Committees to improve children’s learning outcomes in Palorinya refugee settlement.
5 Generate principles to guide the development and implementation of training programs for developing the leadership skills of CMCs to improve children’s Early Learning Outcomes (ELOs) in ECCEcenters in related poly-crisis contexts.
|
Moyo, Palorinya
|
Uganda |
2026-03-24 8:59:47 |
2029-03-24 |
90 |
90 participants drawn from 10 Early Childhood Care and Education (ECCE) centers located within Palorinya Refugee Settlement, encompassing a range of institutional types 3 supported by UNHCR, 2 by Save the Children International, and 5 community-managed (ChildFund Alliance, 2022). |
Self Sponsored |
Social Science and Humanities |
Clinical Trial |
Degree Award |
|
Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Evaluation of The Safety, Efficacy and Stability of SangaDelta® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1194ES
General objectives
To determine the efficacy, safety, and stability of SangaDelta® (Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve ) when applied onto cattle by hand spraying and plunge dipping for tick control.
Specific objectives
The specific objectives of this acaricide field trial will to determine:
i.Efficacy of SangaDelta® when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.Safety of SangaDelta® when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of SangaDelta® when applied onto cattle by plunge dipping for tick control.
|
Mayuge, Lwanika
Mayuge, Buyemba
Mayuge, Lukone
Kumi, Boma
Serere, Okidi
Serere, Akumoi
|
Uganda |
2026-03-19 16:13:37 |
2029-03-19 |
500 cattle above 3 months of age of box sexes and all breeds at the six participating farms |
The study population will constitute cattle of any breed owned by 6 participating farmers in Mayuge [3 farmers], Kumi [one Farmer] and Serere [2 Farmers] district. A total of 500 cattle above 3 months of age will be recruited. Both female, male and neutered cattle will be enrolled into the study |
Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ |
Natural Sciences |
Clinical Trial |
Non-degree Award |
|
Adoke Yeka
ID: UNCST-2021-R004300
|
A Phase 2A study to evaluate the safety, tolerability and pharmacokinetics of a novel antimalarial pyrrolidinamide at different doses and dose durations, in adult patients with uncomplicated P. falciparum malaria
REFNo: HS7237ES
Primary objective:
To investigate the safety and tolerability of GSK3772701 after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria.
Secondary objectives
To evaluate the PK profile of single and repeat oral doses of GSK3772701 in adult patients with
uncomplicated P. falciparum malaria.
Exploratory objectives.
1. To evaluate the efficacy of single and repeat oral doses of GSK3772701 in adult patients with uncomplicated P. falciparum malaria.
2. To characterize the PK/PD relationship.
3. To evaluate P. falciparum genetic polymorphisms and potency of GSK3772701.
4. To assess the safety of GSK3772701 for individual parameters after single and repeat oral doses in adult patients with uncomplicated P. falciparum malaria
|
Tororo, Whole district
|
Uganda |
2026-03-19 16:01:49 |
2029-03-19 |
A total of approximately 70 adult patients, with uncomplicated P. falciparum mono-infection, will be enrolled into the study across 5 cohorts |
Male and female patients aged 18 to 65 years. |
GlaxoSmithKline Research & Development Limited, 79 New Oxford Street, London WC1A 1DG, United Kingdom. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Dennis Muhanguzi
ID: UNCST-2019-R001101
|
Evaluation of The Safety, Efficacy and Stability of Sangaphos® Emulsifiable Concentrate [E.C]: A Randomised Single-Blinded Positive Controlled Multi-Site Acaricide Field Trial
REFNo: NS1171ES
General objectives:
To determine the efficacy, safety, and stability of SangaPhos [Sanga Vet. Chem. Ltd, Kampala Industrial Park, Namanve] when applied onto cattle by hand spraying and plunge dipping for tick control.
Specific objectives
The specific objectives of this acaricide field trial will to determine;
i.Efficacy of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
ii.Safety of Sangaphos® when applied onto cattle by hand spraying and plunge dipping for tick control.
iii.Stability of Sangaphos® when applied onto cattle by plunge dipping for tick control.
|
Kyenjojo, Ntuutu
Kyenjojo, Bwenzi
Kyenjojo, Hima
Serere, Aarapoo
Serere, Aswii
Kumi, Kachaboi
|
Uganda |
2026-03-03 12:23:56 |
2029-03-03 |
633 |
Six Cattle farms from Kyenjojo [n=3], Kumi [n=01] and Serere each with at least 66 cattle will be recruited. Total number of cattle at the six farms = 633. The animals will be at least 2 months of age. Both sexes and any cattle breeds on these farms will be recruited. |
Sanga Vet. Chem. Ltd P.O Box 75164 | Plot 1144, Kampala Industrial Business Park | Kampala-Uganda Tel: 02008000100 | Web: https://www.sangavetchem.com/ |
Natural Sciences |
Clinical Trial |
Non-degree Award |
|
Susan Nabadda Ndidde
ID: UNCST-2020-R014331
|
CLINICAL PERFORMANCE EVALUATION (RETROSPECTIVE STUDY) OF THE STANDARD Q HIV/SYPHILIS/HBsAg TRIPLE TEST
REFNo: HS6651ES
Quantify the proportion of uninterpretable (Invalid) results to gauge operational feasibility based on the invalid rate.,Assess Inter-reader Variability among different operators to ensure consistency in test interpretation and hence reliability in real-world settings.,To assess the diagnostic accuracy of the STANDARD Q HIV/Syphilis/HBsAg Triple Test, a rapid chromatographic immunoassay for simultaneous detection of HIV-1/2 antibodies, syphilis (Treponema pallidum) antibodies, and hepatitis B surface antigen (HBsAg). ,
|
Kampala, National Health Laboratory and Diagnostic Service, Ministry of Health
|
Uganda |
2026-02-12 13:03:06 |
2029-02-12 |
Sample sizes for each disease analyte are calculated to achieve 95% confidence intervals with ±5% margin of error for sensitivity/specificity estimates. Clinical performance will follow the WHO TSS-1, TSS-6 and TSS-13 which require a sample size of up to 1000 samples; to achieve a pre-test clinical performance assessment of the HIV/Syphilis/HBsAg rapid diagnostic test kit, 50 samples of each disease analyte category will be used. |
Stored samples for 18 years and above for both males and females for all tribes will be considered. This retrospective study shall use archived samples from the CPHL biorepository with proof that at the time of sample collection, the source of the selected sample signed a broad consent indicating acceptance of storage for future research use of the remnant of their collected sample. Samples shall be selected from already known specific disease-characterized sets of positive and negative HIV, Syphilis and HBsAg. |
Department of National Health Laboratory and Diagnostic Service, Ministry of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pauline Amuge Mary
ID: UNCST-2023-R005532
|
Bedaquiline Roll-out Evidence in Contacts and People
Living with HIV to prevent TB
(BREACH-TB)
REFNo: HS6975ES
2.1.1.To estimate the safety of 1BDQ and 3HP among
adult, adolescent, and child CCs of DS-TB Index
Patients at high risk of developing TBD, as well
as adult and adolescent PLHIV in high TB burden settings
2.1.2To estimate the safety of 1BDQ and 6 months of
levofloxacin (LFX) among adult, adolescent, and
child CCs of RR-TB Index Patients at high risk of
developing TBD
2.1.3 To estimate on-time treatment completion of
1BDQ and 3HP among adult, adolescent, and
child CCs of DS-TB Index Patients at high risk of
developing TBD, as well as adult and adolescent
PLHIV in high TB-burden settings
2.1.4To estimate on-time treatment completion of
1BDQ and 6 months of levofloxacin (LFX)
among adult, adolescent, and child CCs of RRTB Index Patients at high risk of developing TBD
|
Wakiso, Ssabagabo
|
Uganda |
2026-02-05 22:05:22 |
2029-02-05 |
3130 |
High-risk close contacts (CC) of an individual diagnosed with DS- or RR-TBD
(i.e., the Index Patient) and PLHIV in high-TB burden regions |
United States Agency for International Development |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
AGNES NAGGIRINYA BWANIKA
ID: UNCST-2019-R001126
|
Evaluating the impact on 90-day survival of post-discharge follow-up strategies delivered to adult patients hospitalized with sepsis across a research network in sub-Saharan Africa [Call for Life – Sepsis (C4L-Sepsis)]
REFNo: HS6882ES
To compare baseline demographic and clinical characteristics between participants who were randomized and those who did not meet randomization criteria (screen failures),To evaluate participant quality of life at 28- and 90-days post discharge period within two study arms.,To evaluate the proportion of participants within the two study arms who require re-admission to hospital during the post-discharge period of 90 days,To evaluate proportion of participants within the two study arms who return for scheduled post discharge follow-up visits ,To evaluate the efficacy on 28-day mortality among participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,To evaluate the efficacy on 90-day post-discharge mortality among adult participants hospitalized with sepsis randomized to receive one of two post discharge follow-up strategies – EDI versus EDI plus IVR tool,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co- morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers,To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co- morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. ,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. ,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group,I. To establish the efficacy of vitamin D to the co-morbidity illnesses,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. ,III. To train clinical officers about vitamin D and its application in managing the co-morbidity illnesses under study. This involves training and mentoring of clinical officers so as to acquire knowledge about vitamin D especially in relation to its clinical effects and treatment of malaria, diabetes, HTN, UTIs, and post covid-19 syndrome. This will enable build enough human capacity and willingness to carry out more research about vitamin D,II. To develop prototypes of the efficacy doses of vitamin D for each co-morbidity group. From objective II, the efficacy doses (values) of vitamin D will be recorded. Vitamin D prototypes containing different formulations for each co-morbidity illness will be developed. These will be in form of; solutions, powder and inhalers ,I. To establish the efficacy of vitamin D to the co-morbidity illnesses. This involves giving different doses of vitamin D to study participants in each co-morbidity group in addition to the illness’ conventional drugs while monitoring for change using the monitors of change tests/investigations to ascertain these therapeutic effects of Vitamin D.,To explore vitamin D’s therapeutic efficacy to the co-morbidity diseases (malaria, HTN, diabetes, UTIs and post covid-19 syndrome) under study. This will be achieved by clinical application of vitamin D, assessing and monitoring its effect in the treatment of the respective comorbidity illness as well as developing of different formulations of vitamin D that had effect in each co-morbidity group. ,
|
Masaka, Kimanya
Kampala, Mulago 1
|
Uganda |
2026-01-30 19:36:32 |
2029-01-30 |
353 |
Male and Female adults ≥18 years of all tribes who can understand English and Luganda. |
Stephen Okoboi |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
